Investigation into Proposed Corporate Sales Intensifies

News Summary

Kahn Swick & Foti, LLC, along with former Louisiana Attorney General Charles C. Foti, Jr., is investigating several proposed corporate sales, including those of LENSAR, Inc. and Intra-Cellular Therapies, Inc. Shareholders are urged to assess whether the offers on the table fairly reflect the value of their shares. With significant transactions involving companies like Johnson & Johnson and AstraZeneca, the implications for investors are substantial. Stakeholders are encouraged to engage and ensure their rights are represented as these corporate moves unfold.

Investigation into Corporate Sale Prices Heats Up

In the vibrant city of New Orleans, the renowned law firm Kahn Swick & Foti, LLC (KSF), in collaboration with former Louisiana Attorney General Charles C. Foti, Jr., is diving deep into various proposed corporate sales. This move has sparked interest among shareholders and investors, especially given the hefty price tags involved.

Focus on LENSAR, Inc.

One of the key investigations centers on the proposed sale of LENSAR, Inc. (NasdaqCM: LNSR) to Alcon Inc. (NYSE: ALC). Under the current proposal, LENSAR shareholders stand to receive $14.00 in cash for every share they own, along with an enticing contingent value right that could add up to an additional $2.75 per share, dependent on reaching certain milestones.

KSF’s investigation aims to determine whether this offer reflects the true value of LENSAR, or if shareholders might be missing out on a potential goldmine. For those who feel that the sale is undervaluing LENSAR, reaching out to KSF could be an option worth considering. Managing Partner Lewis S. Kahn is available for discussions at 855-768-1857 or via email at lewis.kahn@ksfcounsel.com. Alternatively, interested parties can also visit KSF’s website for more information.

Diving into Intra-Cellular Therapies

The investigations don’t stop there; KSF is also scrutinizing the proposed sale of Intra-Cellular Therapies, Inc. (NasdaqGS: ITCI) to the global healthcare giant Johnson & Johnson (NYSE: JNJ). Shareholders of Intra-Cellular are poised to receive $132.00 in cash for each share they own. KSF is particularly focused on assessing whether this deal adequately compensates Intra-Cellular shareholders or if there’s more value to be had.

Investigating LogicBio and MGO Global

Additionally, KSF is turning its attention to the proposed sale of LogicBio® Therapeutics, Inc. (NasdaqGM: LOGC) to Alexion, part of AstraZeneca Rare Disease. In this case, LogicBio shareholders would receive $2.07 per share as part of the transaction. As with the other investigations, KSF is keen to uncover if this offer is fair to shareholders.

Meanwhile, the firm is also looking into the merger of MGO Global Inc. (NasdaqCM: MGOL) with Heidmar, Inc. This merger would result in existing MGO shareholders receiving one share of a newly formed company for every share they currently own, retaining approximately 5.6% ownership of the combined entity. KSF’s goal here is to confirm whether this merger process and its terms are equitable for MGO shareholders.

Encouraging Stakeholder Engagement

KSF is actively encouraging affected investors from all investigated transactions to voice their opinions and inquire about their legal rights regarding these proposed sales and mergers. With significant shareholder interests at stake, having a conversation or seeking clarity seems essential.

Those interested can easily get in touch with KSF at no obligation or fee. The law firm’s established email and phone contacts remain open for anyone looking to discuss these critical corporate moves.

In summary, as these corporate sales and mergers unfold, KSF’s investigations aim to ensure that shareholders’ interests are adequately represented and protected. The stakes are high, and the implications of these transactions could have far-reaching effects on investors and the companies involved.

Deeper Dive: News & Info About This Topic

• Business Wire: LENSAR Investor Alert
• Wikipedia: LENSAR
• Business Wire: Intra-Cellular Therapies Investor Alert
• Google Search: Intra-Cellular Therapies
• Business Wire: LogicBio Therapeutics Investor Alert
• Google Scholar: LogicBio Therapeutics
• Business Wire: MGO Global Investor Alert
• Encyclopedia Britannica: MGO Global